Bull case
Kalaris Therapeutics is attractive because TH103 is engineered to solve the biggest commercial weakness in wet AMD—frequent redosing—through high-affinity VEGFR1 binding and HSPG-mediated retinal retention, which early Phase Ia data suggest can deliver both strong efficacy and better durability from a single dose. In treatment-naive patients (n=13), TH103 produced about a +10-letter BCVA gain, roughly 129 µm CST reduction, near-complete fluid clearance, and 31% of patients needed no retreatment through six months, with safety improving after manufacturing refinements reduced process impurities. With wet AMD representing a $15B+ market, and management/modeling pointing to about $1.6B of peak sales by 2040 and roughly 35 issued/allowed patents plus 27 pending applications as of December 2025, the stock’s outlook rests on a credible path to meaningful share capture and durable exclusivity.